Suppr超能文献

非裔美国前列腺癌患者中与疾病进展相关的 DNA 甲基化图谱。

DNA methylation profiles in African American prostate cancer patients in relation to disease progression.

机构信息

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC, United States.

出版信息

Genomics. 2019 Jan;111(1):10-16. doi: 10.1016/j.ygeno.2016.02.004. Epub 2016 Feb 21.

Abstract

This study examined whether differential DNA methylation is associated with clinical features of more aggressive disease at diagnosis and prostate cancer recurrence in African American men, who are more likely to die from prostate cancer than other populations. Tumor tissues from 76 African Americans diagnosed with prostate cancer who had radical prostatectomy as their primary treatment were profiled for epigenome-wide DNA methylation levels. Long-term follow-up identified 19 patients with prostate cancer recurrence. Twenty-three CpGs were differentially methylated (FDR q≤0.25, mean methylation difference≥0.10) in patients with vs. without recurrence, including CpGs in GCK, CDKL2, PRDM13, and ZFR2. Methylation differences were also observed between men with metastatic-lethal prostate cancer vs. no recurrence (five CpGs), regional vs. local pathological stage (two CpGs), and higher vs. lower tumor aggressiveness (one CpG). These results indicate that differentially methylated CpG sites identified in tumor tissues of African American men may contribute to prostate cancer aggressiveness.

摘要

本研究旨在探讨在被诊断为更具侵袭性疾病的临床特征和前列腺癌复发方面,DNA 甲基化是否存在差异,而非洲裔美国男性比其他人群更有可能死于前列腺癌。对 76 名接受根治性前列腺切除术作为主要治疗方法的被诊断患有前列腺癌的非洲裔美国人的肿瘤组织进行了全基因组 DNA 甲基化水平的特征分析。长期随访确定了 19 名前列腺癌复发患者。在有和没有复发的患者中,有 23 个 CpG 表现出差异甲基化(FDR q≤0.25,平均甲基化差异≥0.10),包括 GCK、CDKL2、PRDM13 和 ZFR2 中的 CpG。在转移性致命性前列腺癌与无复发(五个 CpG)、局部与局部病理分期(两个 CpG)以及肿瘤侵袭性较高与较低(一个 CpG)的男性之间,也观察到了甲基化差异。这些结果表明,在非洲裔美国男性的肿瘤组织中鉴定出的差异甲基化 CpG 位点可能与前列腺癌的侵袭性有关。

相似文献

1
DNA methylation profiles in African American prostate cancer patients in relation to disease progression.
Genomics. 2019 Jan;111(1):10-16. doi: 10.1016/j.ygeno.2016.02.004. Epub 2016 Feb 21.
5
Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.
Prostate. 2015 Dec;75(16):1941-50. doi: 10.1002/pros.23093. Epub 2015 Sep 18.
6
Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
Clin Epigenetics. 2016 Sep 15;8:97. doi: 10.1186/s13148-016-0260-z. eCollection 2016.
7
Tumor suppressor function of PGP9.5 is associated with epigenetic regulation in prostate cancer--novel predictor of biochemical recurrence after radical surgery.
Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):487-96. doi: 10.1158/1055-9965.EPI-11-0970. Epub 2012 Jan 13.
8
Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes.
Cancer. 2016 Jul 15;122(14):2168-77. doi: 10.1002/cncr.30045. Epub 2016 May 3.
10
Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence.
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1331-9. doi: 10.1158/1055-9965.EPI-13-1000. Epub 2014 Apr 9.

引用本文的文献

2
Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2.
ACS Med Chem Lett. 2024 Jul 3;15(8):1325-1333. doi: 10.1021/acsmedchemlett.4c00219. eCollection 2024 Aug 8.
3
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape.
Cancer Metastasis Rev. 2024 Dec;43(4):1233-1255. doi: 10.1007/s10555-024-10193-8. Epub 2024 Jun 20.
4
Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2.
bioRxiv. 2024 May 14:2024.05.12.593776. doi: 10.1101/2024.05.12.593776.
5
Tumor suppressive miR-99b-5p as an epigenomic regulator mediating mTOR/AR/SMARCD1 signaling axis in aggressive prostate cancer.
Front Oncol. 2023 Nov 7;13:1184186. doi: 10.3389/fonc.2023.1184186. eCollection 2023.
6
Genetic and biological drivers of prostate cancer disparities in Black men.
Nat Rev Urol. 2024 May;21(5):274-289. doi: 10.1038/s41585-023-00828-w. Epub 2023 Nov 14.
7
Alterations in the Epigenetic Machinery Associated with Prostate Cancer Health Disparities.
Cancers (Basel). 2023 Jul 1;15(13):3462. doi: 10.3390/cancers15133462.
8
Genomic, epigenomic, and transcriptomic signatures of prostate cancer between African American and European American patients.
Front Oncol. 2023 Feb 28;13:1079037. doi: 10.3389/fonc.2023.1079037. eCollection 2023.

本文引用的文献

1
Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer.
Expert Rev Mol Diagn. 2015;15(9):1211-24. doi: 10.1586/14737159.2015.1069711. Epub 2015 Jul 15.
3
Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort.
Prostate. 2015 Sep;75(13):1354-62. doi: 10.1002/pros.23016. Epub 2015 May 18.
4
Health disparities and cancer: racial disparities in cancer mortality in the United States, 2000-2010.
Front Public Health. 2015 Apr 15;3:51. doi: 10.3389/fpubh.2015.00051. eCollection 2015.
6
Genome-wide differentially methylated genes in prostate cancer tissues from African-American and Caucasian men.
Epigenetics. 2015;10(4):319-28. doi: 10.1080/15592294.2015.1022019. Epub 2015 Apr 11.
7
limma powers differential expression analyses for RNA-sequencing and microarray studies.
Nucleic Acids Res. 2015 Apr 20;43(7):e47. doi: 10.1093/nar/gkv007. Epub 2015 Jan 20.
8
Cancer statistics, 2015.
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
9
Income inequality and treatment of African American men with high-risk prostate cancer.
Urol Oncol. 2015 Jan;33(1):18.e7-18.e13. doi: 10.1016/j.urolonc.2014.09.005. Epub 2014 Oct 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验